停用地舒单抗长期治疗后的显著骨丢失:FREEDOM研究事后分析
本研究纳入38名曾接受地舒单抗(DMAb)治疗7或10年的绝经后女性,停药后随访约17个月。结果显示腰椎、股骨颈和全髋骨密度分别下降8.1%、6%和8.4%,并丢失治疗期间获得骨量的35.5%、44.6%和103.3%;5例发生脆性骨折。作者结论为停药后出现快速骨丢失,需进一步研究骨折风险及双膦酸盐转换的作用。
要点
- 停用地舒单抗后腰椎、股骨颈和全髋骨密度分别下降8.1%、6%和8.4%。
- 分别丢失治疗期间骨量获得的35.5%(腰椎)、44.6%(股骨颈)和103.3%(全髋)。
- 38例中5例(13.15%)发生脆性骨折,包括1例腕部骨折和4例椎体骨折。
核心结论
- 停用地舒单抗治疗后出现快速骨丢失。
- 需进一步研究停药后患者骨折风险是否更高、哪些患者风险最高,以及长期转换至双膦酸盐的作用。
研究设计与样本
- FREEDOM研究及其扩展研究的事后随访研究,邀请曾参与FREEDOM研究的女性参加。
- 共38名绝经后女性完成研究程序,平均年龄81±3.4岁,均在接受地舒单抗治疗7或10年后停药,停药后未接受双膦酸盐。
- 测量腰椎和髋部骨密度及脊柱X线,并与治疗期间最后一次值比较。
主要发现
- 地舒单抗末次给药至随访 visit 的平均间隔为17个月(范围16-20个月)。
- 骨密度在所有部位均显著下降:腰椎-8.1%,股骨颈-6%,全髋-8.4%。
- 考虑治疗期间获得和治疗后丢失,腰椎总获得量的35.5%、股骨颈总获得量的44.6%、全髋总获得量的103.3%被丢失。
- 5例(5/38,13.15%)发生脆性骨折:1例腕部骨折,4例椎体骨折;3例发生1处椎体骨折,其中1例有2处椎体骨折。
- 实验室平均值为:CTX=996±307 pg/ml(正常值550±226 pg/ml);骨钙素=55.2±18.6 ng/ml(正常值42 ng/ml);25羟维生素D=23.7±6.9 ng/ml。
局限性
- 需进一步研究以评估停用地舒单抗后患者骨折风险是否更高、哪些患者风险最高,以及长期转换至双膦酸盐的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: We evaluate 38 elderly women who had received long-term denosumab treatment after stopping the drug. Taking into account the gain during treatment and the loss after stopping treatment, they lost 35.5% of the total gain in the spine, 44.6% of the total gain in the femoral neck, and 103.3% in the total hip. INTRODUCTION: Denosumab (DMAb) is a soluble inhibitor of the receptor activator of nuclear factor-kappaB ligand (RANKL) and, therefore, does not incorporate into the bone matrix. Consistently, DMAb discontinuation is associated with reversal of the effects attained with treatment. PURPOSE: The aim of this study is to assess changes in BMD after a year of discontinuation of DMAb in a group of postmenopausal women treated with DMAb for 7 or 10 years. Secondly, is to evaluate the occurrence of fragility fractures. METHODS: Women who had participated in the FREEDOM study and its extension were invited to participate in this follow-up study. BMD at LS and hip and spine X-rays were obtained. Results were compared to the last value obtained while in treatment to assess changes after discontinuation. RESULTS: Thirty-eight women, mean age: 81 ± 3.4 years completed study procedures; none had received bisphosphonates after stopping DMAb. Mean gap time between DMAb last dose and the follow-up visit was 17 months (range 16-20 months). Bone mineral density (BMD) decreased significantly in all regions: - 8.1% in LS, - 6% in FN, and - 8.4% in TH. Five (5/38, 13.15%) patients had a fragility fracture, one suffered a wrist fracture, and four experienced vertebral fractures. Three patients suffered one vertebral fracture and one of them had two vertebral fractures. Laboratory results showed the following mean values: CTX = 996 ± 307 pg/ml (normal values 550 ± 226 pg/ml); osteocalcin = 55.2 ± 18.6 ng/ml (normal value 42 ng/ml); and 25 OH vitamin D = 23.7 ± 6.9 ng/ml. CONCLUSION: Our results describe the rapid bone loss occurring after cessation of denosumab treatment. Further studies are needed to assess if patients have a higher risk of fracture after stopping DMAb and if so, which patients have the highest risk, and assess the role of transitioning to bisphosphonates in the long term.
引用
- Zanchetta MB, Boailchuk J, Massari F, et al. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study. Osteoporos Int. 2017. PMID: 28975362. doi:10.1007/s00198-017-4242-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。